Display options
Cite
Eggen AC, Wind TT, Bosma I, et al. Value of screening and follow-up brain MRI scans in patients with metastatic melanoma. Cancer Med. 2021;10(23):8395-8404doi: 10.1002/cam4.4342.
Eggen, A. C., Wind, T. T., Bosma, I., Kramer, M. C. A., van Laar, P. J., van der Weide, H. L., Hospers, G. A. P., & Jalving, M. (2021). Value of screening and follow-up brain MRI scans in patients with metastatic melanoma. Cancer medicine, 10(23), 8395-8404. https://doi.org/10.1002/cam4.4342
Eggen, Annemarie C, et al. "Value of screening and follow-up brain MRI scans in patients with metastatic melanoma." Cancer medicine vol. 10,23 (2021): 8395-8404. doi: https://doi.org/10.1002/cam4.4342
Eggen AC, Wind TT, Bosma I, Kramer MCA, van Laar PJ, van der Weide HL, Hospers GAP, Jalving M. Value of screening and follow-up brain MRI scans in patients with metastatic melanoma. Cancer Med. 2021 Dec;10(23):8395-8404. doi: 10.1002/cam4.4342. Epub 2021 Nov 05. PMID: 34741440; PMCID: PMC8633235.
Copy Download .nbib Format: NLM
Share it on

Cancer Med. 2021 Dec;10(23):8395-8404. doi: 10.1002/cam4.4342. Epub 2021 Nov 05.

Value of screening and follow-up brain MRI scans in patients with metastatic melanoma.

Cancer medicine

Annemarie C Eggen, Thijs T Wind, Ingeborg Bosma, Miranda C A Kramer, Peter Jan van Laar, Hiska L van der Weide, Geke A P Hospers, Mathilde Jalving

Affiliations

  1. Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  2. Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  3. Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  4. Department of Radiology, Ziekenhuisgroep Twente, Almelo, and Hengelo, Almelo, The Netherlands.
  5. Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

PMID: 34741440 PMCID: PMC8633235 DOI: 10.1002/cam4.4342

Abstract

BACKGROUND: Novel treatments make long-term survival possible for subsets of patients with melanoma brain metastases. Brain magnetic resonance imaging (MRI) may aid in early detection of brain metastases and inform treatment decisions. This study aimed to determine the impact of screening MRI scans in patients with metastatic melanoma and follow-up MRI scans in patients with melanoma brain metastases.

METHODS: This retrospective cohort study included patients diagnosed with metastatic melanoma or melanoma brain metastases between June 2015 and January 2018. The impact of screening MRI scans was evaluated in the first 2 years after metastatic melanoma diagnosis. The impact of follow-up MRI scans was examined in the first year after brain metastases diagnosis. The number of MRI scans, scan indications, scan outcomes, and changes in treatment strategy were analyzed.

RESULTS: In total, 116 patients had no brain metastases at the time of the metastatic melanoma diagnosis. Twenty-eight of these patients (24%) were subsequently diagnosed with brain metastases. Screening MRI scans detected the brain metastases in 11/28 patients (39%), of which 8 were asymptomatic at diagnosis. In the 96 patients with melanoma brain metastases, treatment strategy changed after 75/168 follow-up MRI scans (45%). In patients treated with immune checkpoint inhibitors, the number of treatment changes after follow-up MRI scans was lower when patients had been treated longer.

CONCLUSION(S): Screening MRI scans aid in early detection of melanoma brain metastases, and follow-up MRI scans inform treatment strategy. In patients with brain metastases responding to immune checkpoint inhibitors, treatment changes were less frequently observed after follow-up MRI scans. These results can inform the development of brain imaging protocols for patients with immune checkpoint inhibitor sensitive tumors.

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Keywords: brain metastases; early diagnosis; melanoma; neuro-oncology; neuroimaging

References

  1. Cancer Med. 2021 Dec;10(23):8395-8404 - PubMed
  2. Cancer. 2014 Feb 1;120(3):433-41 - PubMed
  3. Melanoma Res. 2018 Apr;28(2):126-133 - PubMed
  4. Ann Oncol. 2020 Nov;31(11):1435-1448 - PubMed
  5. J Neurosurg. 2011 Mar;114(3):763-8 - PubMed
  6. Cancer. 2008 Apr 15;112(8):1827-34 - PubMed
  7. Melanoma Res. 2015 Feb;25(1):75-9 - PubMed
  8. Melanoma Res. 2013 Feb;23(1):21-6 - PubMed
  9. Handb Clin Neurol. 2018;149:75-88 - PubMed
  10. Cancer. 2019 Nov 1;125(21):3776-3789 - PubMed
  11. J Neurooncol. 2021 Sep;154(2):197-203 - PubMed
  12. Lancet Oncol. 2015 Jun;16(6):e270-8 - PubMed
  13. Neuro Oncol. 2021 Nov 2;23(11):1961-1973 - PubMed
  14. Melanoma Res. 2014 Feb;24(1):54-60 - PubMed
  15. Lancet Oncol. 2018 May;19(5):672-681 - PubMed
  16. N Engl J Med. 2018 Aug 23;379(8):722-730 - PubMed
  17. Cancer. 2015 Nov 1;121(21):3836-43 - PubMed
  18. Eur J Cancer. 2006 Feb;42(3):342-50 - PubMed
  19. Ann Oncol. 2021 Nov;32(11):1332-1347 - PubMed
  20. Lancet Oncol. 2017 Jul;18(7):863-873 - PubMed
  21. J Neurooncol. 1999;44(3):275-81 - PubMed
  22. Lancet Oncol. 2012 May;13(5):459-65 - PubMed
  23. Ann Oncol. 2019 Dec 1;30(12):1884-1901 - PubMed
  24. J Clin Oncol. 2019 Jan 1;37(1):52-60 - PubMed
  25. N Engl J Med. 2015 Jan 1;372(1):30-9 - PubMed
  26. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1008-1015 - PubMed
  27. Int J Cancer. 2020 Mar 15;146(6):1479-1489 - PubMed
  28. Handb Clin Neurol. 2018;149:27-42 - PubMed
  29. Neurosurgery. 2003 May;52(5):1066-73; discussion 1073-4 - PubMed
  30. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1113-1118 - PubMed
  31. Breast Cancer Res Treat. 2020 Apr;180(2):279-300 - PubMed
  32. Prog Neurol Surg. 2019;34:110-124 - PubMed
  33. Eur J Cancer. 2020 Jun;132:187-198 - PubMed
  34. J Neurooncol. 2018 Oct;140(1):83-88 - PubMed

Publication Types